PHOENIX, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Medifocus, Inc. (MFS.V) (OTCQB: MDFZF) (“the Company”) is a Biotechnology Company with a portfolio of medical technologies that utilize patented Focal Thermal Technology to treat conditions ranging from prostate diseases to breast cancer. General Manager, John Mon, and Medical Director, Dr. Stuart E. Katz, M.D. talked with Stock Day’s Everett Jolly.
“The company has two blockbuster products, one in women’s health and one in men’s health,” explained Mon. “The first product is called the APA 1000 and that’s for the treatment of breast cancer. The second product is the FDA approved product called Prolieve® and that is for the treatment of enlarged prostates or BPH.”
Mon went on to say that the company has approximately 100 issued patents in the U.S. and foreign countries. He then went over both platforms for the two devices. For the breast cancer treatment platform, he said it was originally invented at MIT using microwaves to detect and destroy enemy missiles.
“Working with MIT researchers we developed a comprehensive, dedicated breast cancer treatment system which focuses microwaves to destroy breast cancer tissue,” said Mon.
He then explained Medifocus Inc. has undergone a series of FDA sanctioned studies, two of the randomized studies have been approved by the FDA. One was for early stage small tumors to improve the results of negative margins during surgery. The second study focused on downstaging locally advanced breast tumors. He says both studies showed positive results.
“The FDA has given us the go ahead to begin a pivotal phase 3 study, not many companies of our size have approval to begin a pivotal phase 3 study,” explained Mon.
He then said that the FDA approved Prolieve® device has already been used to treat over 100,000 men in the U.S. Dr. Katz then said he joined Medifocus Inc. to help bring this technology to other Urologists.
“I’m a very strong and enthusiastic proponent of Thermotherapy, using heat to treat several, and various, diseases,” said Katz. “It’s an exciting area. We’ve just begun to explore the benefits of Thermotherapy, both in terms of its direct toxicity to tissues, specifically cancers, as well as the augmenting effect on checkpoint inhibitors.”
Katz went on to say that Prolieve® is a safe alternative to other medicines and surgery and is the only transurethral thermotherapy dilation device available. He says they have patented the dilating balloon combination and that it is able provide immediate symptomatic relief with a safety profile that exceeds any competitors.
“The procedure is done under local anesthesia, it takes about 45 minutes to do and we do it in the office,” said Katz. “Almost 90% of patients who have the treatment are almost immediately able to urinate on their own without the need of a Foley catheter.”
Jolly then mentioned that small companies like Medifocus Inc. normally don’t have revenue, let alone FDA approval of a product. He wanted to know what the financial turnaround for the company could be considering their stock is trading at a tad bit under 2 cents with a cap of just over $3 million.
“We are in a very good position,” said Mon. “We have a product that actually generates revenue. We went through a restructuring about two years ago and have been able to turn the company around. In our last reporting of our last year we actually had a positive net cash gained from operations. That is no doubt a major turnaround and shows stability in a small company. You would be hard pressed to find another small company with a positive net cash of operations.”
To listen to the entire interview with Mon and Katz, follow this link: https://upticknewswire.com/featured-interview-gm-john-mon-and-dr-katz-of-medifocus-inc-otcqb-mdfzf/
About Medifocus, Inc.:
Medifocus, Inc. (TSXV-MFS) (OTC-MDFZF) is a Biotechnology Company with a portfolio of medical technologies that utilize patented Focal Thermal Technology to treat conditions ranging from Prostate Diseases to Breast Cancer. Its Prolieve® Thermodilatation™ System offers symptomatic relief to men with Benign Prostatic Hyperplasia (BPH) through a simple, 45-minute, in-office treatment. Prolieve® is both FDA and Medicare approved for treating symptomatic BPH with over 100,000 cases performed in the U.S. alone, and with proven long-term safety, efficacy and durability. Its APA 1000 Breast Cancer Treatment System was licensed from Massachusetts Institute of Technology and developed by the Medifocus team. The Targeted Focal Thermotherapy has been demonstrated in Phase 2 clinical trials to offer significantly better tumor shrinkage in patients treated with the combined Chemothermal therapy compared those treated with Chemotherapy alone. APA 1000 was also shown to be effective in reducing margin positivity among patients treated with such thermotherapy prior to lumpectomy.
John Mon, General Manager
10240 Old Columbia Rd. Suite G
Columbia, MD 21046
United States Phone:
This news release contains “forward-looking statements” and “forward-looking information”, which may not be based on historical facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with respect to the benefit to Medifocus’ future growth resulting from the acquisition of additional intellectual property rights, additional treatment possibilities and the expectation that sales from Prolieve® may accelerate as a consequence. Forward-looking statements are frequently characterized by words such as “plan,” “expect,” “project,” “intend,” “believe,” “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments.
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/